Join a Clinical Trial
Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each clinical trial.
Clinical Trial Details
A Study of Evorpacept (ALX148) With Enfortumab Vedotin for Subjects With Urothelial Carcinoma (ASPEN-07)
Complete Title: A PHASE 1, OPEN-LABEL, MULTICENTER, SAFETY, PHARMACOKINETIC, PHARMACODYNAMIC STUDY OF ALX148 IN COMBINATION WITH ENFORTUMAB VEDOTIN AND/OR OTHER ANTICANCER THERAPIES IN SUBJECTS WITH UROTHELIAL CARCINOMA (ASPEN-07)
Trial Phase: I
Investigator: Petros Grivas
AT148007 is a Phase 1, open-label, multicenter, safety, pharmacokinetic, pharmacodynamic study of ALX148 in combination with enfortumab vedotin and/or other anticancer therapies in subjects with urothelial carcinoma.
Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.
Contact Us
If you are seeking to schedule an appointment, we are here to help. You can either call us or fill out our online appointment request form.
Adult
I
Petros Grivas
RG1123398
NCT05524545
A PHASE 1, OPEN-LABEL, MULTICENTER, SAFETY, PHARMACOKINETIC, PHARMACODYNAMIC STUDY OF ALX148 IN COMBINATION WITH ENFORTUMAB VEDOTIN AND/OR OTHER ANTICANCER THERAPIES IN SUBJECTS WITH UROTHELIAL CARCINOMA (ASPEN-07)